Amneal Pharmaceuticals (AMRX) Cash from Operations Growth (3y) (2020 - 2026)
Amneal Pharmaceuticals (AMRX) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.28 Bn | 21.13 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 20.54 Bn | 20.54 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.55 Bn | 12.12 Bn | 785.00 Mn | 27.85% |
| 10 | Amneal Pharmaceuticals | 5.69 Bn | 5.69 Bn | 320.11 Mn | -29.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.89% |
| Dec 31, 2025 | 96.57% |
| Sep 30, 2025 | 8.18% |
| Jun 30, 2025 | 38.69% |
| Mar 31, 2025 | -60.52% |
| Dec 31, 2024 | 23.12% |
| Sep 30, 2024 | 19.84% |
| Jun 30, 2024 | 40.33% |
| Mar 31, 2024 | -26.61% |
| Dec 31, 2023 | 8.63% |
| Sep 30, 2023 | 22.04% |
| Jun 30, 2023 | -27.31% |
| Mar 31, 2023 | 41.78% |
| Dec 31, 2022 | 22.93% |
| Sep 30, 2022 | -12.55% |
| Jun 30, 2022 | -99.59% |
| Mar 31, 2022 | 45.97% |
| Dec 31, 2021 | -37.54% |
| Sep 30, 2021 | 9.85% |
| Jun 30, 2021 | 19.24% |